India's drugmakers need more time to meet international standards: industry group | Reuters

By Zeba Siddiqui | MUMBAI MUMBAI India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.U.S. and European Union regulators have called on India's $16 billion pharmaceutical industry to step up their efforts if it wants to continue to dominate the generic drugs sector.'When you go plant by plant and want to assess whether something is working or not, this is a time consuming process,' D. Shah, secretary general of the Indian Pharmaceutical Association (IPA), told Reuters late Tuesday.'It may go beyond 5 years as well.'The IPA, which counts 20 of the country's largest drugmakers as its members, has formulated a five-year quality improvement plan that includes training employees and automating procedures

Reuters May 17, 2017 17:00:48 IST
India's drugmakers need more time to meet international standards: industry group
| Reuters

Indias drugmakers need more time to meet international standards industry group
 Reuters

By Zeba Siddiqui
| MUMBAI

MUMBAI India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.U.S. and European Union regulators have called on India's $16 billion pharmaceutical industry to step up their efforts if it wants to continue to dominate the generic drugs sector."When you go plant by plant and want to assess whether something is working or not, this is a time consuming process," D. Shah, secretary general of the Indian Pharmaceutical Association (IPA), told Reuters late Tuesday."It may go beyond 5 years as well."The IPA, which counts 20 of the country's largest drugmakers as its members, has formulated a five-year quality improvement plan that includes training employees and automating procedures.

Shah said the plan was currently being implemented at six of the country's top drugmakers, and that it would eventually be rolled out to the rest of the industry."We have to train every employee in both manufacturing and quality," said Shah, noting that it means training 40,000-50,000 employees at just the top six drug companies.STRUGGLING TO IMPROVE

The industry has struggled to improve their factory processes and train staff since 2013, when major violations were found at India's then-largest drugmaker Ranbaxy Laboratories.Complaints from regulators have ranged from issues over hygiene and maintenance to concerns over falsifying manufacturing-related test results and data.Dr Reddy's Laboratories, India's No. 2 drugmaker, continues to work on resolving data integrity problems found by the FDA in November 2015 at a key plant to produce cancer drugs. While its larger rival, Sun Pharmaceutical Industries, has not been able to get a clearance on two plants sanctioned by the FDA in 2013 and 2014 despite remediation efforts.

So far this year, 14 Indian companies have received safety notices from the U.S. Food and Drug Administration, the regulator that has issued the majority of sanctions against its industry.Shah said IPA was working to ensure "companies do not get faulted on the same thing again and again," and reach a compliance level that appeases the FDA.Some in the industry say the severity of the issues the FDA has been finding in India has been increasing and that the five-year timeline laid out was too long. "If companies follow all procedures, they should be able to resolve their issues soon," said Bharat Celly, an analyst with Equirus Securities."But if they think they can still get away with altering data and being dishonest with the FDA, they are aggravating their problems." (Reporting by Zeba Siddiqui in Mumbai; Editing by Randy Fabi)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Thousands protest against French bill to curb identification of police
World

Thousands protest against French bill to curb identification of police

By Lucien Libert and Dominique Vidalon PARIS (Reuters) - Several thousand people protested in Paris on Saturday against a bill that would make it a crime to circulate an image of a police officer's face with the intention that they should be harmed. Supporters say police officers and their families need protection from harassment, both online and in person when off duty. Opponents say the law would infringe journalists' freedom to report, and make it harder to hold police accountable for abuses such as excessive use of force - a growing public concern

UK's Sunak says he hopes for a Brexit deal but not at any price
World

UK's Sunak says he hopes for a Brexit deal but not at any price

LONDON (Reuters) - British finance minister Rishi Sunak has said there is genuine progress in Brexit talks with the European Union, but that it would be better to walk away from a bad trade deal than tie Britain's hands in the future. Sunak, one of the few members of Prime Minister Boris Johnson's senior ministerial team to have emerged from the COVID pandemic with an enhanced reputation, was thought to be one of the leading voices in the cabinet who wanted a free trade deal with the EU. He told the Sunday Times that he hoped Britain and the European Union would secure an agreement

Lebanon's president pledges to revive forensic audit of central bank
World

Lebanon's president pledges to revive forensic audit of central bank

BEIRUT (Reuters) - Lebanese President Michel Aoun said on Saturday that a forensic audit of the central bank was vital to combat corruption and that he would put it back on track following the withdrawal of the consultancy hired to do the audit.